{
Penumbra, Inc.

Companies

}
001122334455554433221100
001122334455554433221100

penumbra insider sales and hedge fund activity highlight market dynamics

Penumbra's executive vice president now owns 64,044 shares valued at over $15 million, reflecting a 0.93% decrease in ownership. In the past 90 days, insiders sold 33,819 shares worth $8.1 million, while hedge funds hold 88.88% of the stock. Analysts maintain a "Moderate Buy" rating, with target prices ranging from $250 to $305.
MarketBeat
Penumbra, Inc. USA Johanna Roberts Lambert Shiu
Finance & Economy, Market Report
14:30 21.01.2025

ubs initiates buy rating for penumbra with strong revenue growth forecast

UBS has initiated coverage on Penumbra with a Buy rating and a price target of $305, citing a projected 14% revenue CAGR through 2029, driven by a strong product launch cycle and growth in the venous thromboembolism market. The stock, currently trading at $263.69, is expected to maintain a premium valuation in the high-growth MedTech sector, supported by a gross profit margin of 63% and a 17% revenue growth over the past year. Other analysts, including Oppenheimer and Wells Fargo, have also expressed positive outlooks on Penumbra, anticipating continued double-digit growth and successful product introductions.
in.investing.com
Abbott Laboratories EDWARDS LIFESCIENCES BOSTON SCIENTIFIC Intuitive Surgical, Inc. Inari Medical Inc Medtronic plc DexCom, Inc. Penumbra, Inc. Stryker Corporation USA Joe Biden Matthew Blackman Show more
Business & Industry, Market Report
11:02 21.01.2025

ubs gives penumbra buy rating forecasts 14 percent revenue growth through 2029

UBS has initiated coverage of Penumbra shares with a Buy rating, forecasting a 14% compound annual growth rate (CAGR) in revenue through 2029. This positive outlook highlights the company's potential for significant growth in the coming years.
msn.com
United States Dollar Penumbra, Inc. USA
Finance & Economy, Market Report
11:01 21.01.2025

healthcare innovation portfolio targets advancements in pharmaceuticals and medical technologies

The convergence of science and technology is transforming healthcare, with Syfe's Healthcare Innovation portfolio offering diversified investment across genomics, biotechnology, pharmaceuticals, healthcare services, and medical devices. This portfolio includes six carefully selected ETFs, providing exposure to leading companies and innovations in the sector, while managing risks associated with long-term healthcare investments. With no minimum investment and low fees, it aims to capitalize on the future of healthcare advancements.
Connect
Masimo Corporation Vertex Pharmaceuticals Incorporated Abbott Laboratories GE HealthCare Technologies Inc. AtriCure, Inc. Regeneron Pharmaceuticals, Inc. Intuitive Surgical, Inc. CRISPR Therapeutics AG Veeva Systems Inc. Johnson & Johnson Cigna Integra LifeSciences Holdings Corporation CVS Health Corporation Stryker Corporation UnitedHealth Group Incorporated Amgen Inc. Penumbra, Inc. Alphatec Holdings, Inc. UCB SA Boston Scientific Corporation Eli Lilly and Company USA BEL Beigene Revolution Medicines Gilead Sciences Exelixis Incyte Show more
Finance & Economy, Market Report
02:52 13.11.2024
Trending
Subcategory
Corporate News Stock Market Updates Industry Trends Finance Mergers & Acquisitions Industry Mergers & Acquisitions Global Financial Events Market Analysis and Predictions Banking Regulations Financial Scams and Security Retail and Consumer Goods CEO Changes Global Trade Developments Central Bank Actions Supply Chain Management Startups & Entrepreneurship Government Policies Government Economic Policies AI Innovations Energy Sector Developments Economic Sanctions
Countries:
USA CHN IND GBR CHE DEU ITA FRA JPN SGP ARE AUS NLD TWN CAN RUS IRL VNM DNK THA
Companies:
Barclays PLC Tesla, Inc. JPMorgan Chase & Co. Bank of America Corporation The Goldman Sachs Group, Inc. NVIDIA Corporation Wells Fargo & Company Apple Inc. UniCredit S.p.A. UBS Group AG Banco BPM S.p.A. Amazon.com, Inc. Citigroup Inc. Google Inc. Credit Suisse Real Estate Fund Siat Deutsche Bank RV Global PP BNP Paribas SA Commerzbank AG Lloyds Banking Group plc Huawei Technologies CO. Ltd.
Currencies:
United States Dollar Euro Indian Rupee Swiss Franc British Pound Sterling Chinese Yuan Japanese Yen Hong Kong Dollar Danish Krone Australian Dollar United Arab Emirates Dirham Swedish Krona Singapore Dollar South Korean Won Canadian Dollar Russian Ruble Malaysian Ringgit Offshore Chinese Yuan Kuwaiti Dinar Ghanaian Cedi
People:
Donald Trump Elon Musk Jerome Powell Joe Biden Dan Ives Brian Moynihan Tom O'Malley Akhil Gupta Andrea Orcel Jamie Dimon Mihir Doshi Soha Nashaat Cristian Nedelcu Robin Leopold David M. Solomon Patrick Ramsey Scott Bessent Ian Rockliffe Warren Buffett Brandt Montour

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Links

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings
Reset settings
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.